D-0637-2024 Class II Ongoing

Recalled by Teva Pharmaceuticals USA, Inc — Parsippany, NJ

FDA drug recall D-0637-2024 was initiated by Teva Pharmaceuticals USA, Inc on Aug 8, 2024 and is designated Class II. Reason for recall: Superpotent Drug The recall status is ongoing. Affected quantity: 7,080 unit dose packets.

Recall details

Product Type
Drugs
Report Date
Aug 28, 2024
Initiation Date
Aug 8, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
7,080 unit dose packets

Product description

Testosterone Gel, 1.62%, (Alcohol 80% v/v), 30 unit-dose packets, Rx Only, Teva Pharmaceuticals, USA, Inc. North Wales, PA 19454, NDC 0591-2925-30. Packet NDC # 0591-2925-32 Carton NDC # 0591-2925-30

Reason for recall

Superpotent Drug

Distribution pattern

Product was distributed nationwide within the United States

Code information

Lot #: 100042386, Exp. Date 06/2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0637-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0637-2024. Report a data issue: hello@regdatalab.com.